Related Experiment Video
Updated: May 20, 2026

Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis
Published on: June 24, 2018
FGF-23 in children with CKD: a new player in the development of CKD-mineral and bone disorder
Ekaterini Siomou1, Constantinos J Stefanidis
1Department of Child Health, Medical School, University of Ioannina, Ioannina, Greece. stefanid@hol.gr
Insights
Fibroblast growth factor-23 (FGF-23) is elevated early in children with chronic kidney disease (CKD), preceding other mineral and bone disorder (CKD-MBD) markers. Targeting this FGF-23 axis may prevent bone deformities and growth issues in pediatric CKD.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Mineral and Bone Metabolism
Background:
- Chronic kidney disease (CKD) in children causes mineral and bone disorders (CKD-MBD), leading to skeletal abnormalities and growth issues.
- Traditional understanding implicates vitamin D, parathyroid hormone (PTH), calcium (Ca), and phosphate (P) disturbances in CKD-MBD pathogenesis.
- Emerging research highlights fibroblast growth factor-23 (FGF-23) as a critical regulator of phosphate and vitamin D metabolism.
Purpose of the Study:
- To investigate the role of FGF-23 in the early stages of CKD-MBD in pediatric populations.
- To determine if elevated FGF-23 levels precede other biochemical markers of CKD-MBD.
- To explore FGF-23 as a potential therapeutic target for managing CKD-MBD in children.
Main Methods:
- Analysis of FGF-23 levels in pediatric CKD patients.
- Correlation of FGF-23 levels with serum Ca, P, and PTH concentrations.
- Review of existing literature on FGF-23's role in mineral metabolism.
Main Results:
- Elevated FGF-23 levels were observed early in pediatric CKD, prior to detectable abnormalities in serum Ca, P, or PTH.
- Increased FGF-23 induces phosphaturia and suppresses vitamin D synthesis, contributing to negative phosphate balance.
- FGF-23 acts independently of PTH in regulating phosphate homeostasis.
Conclusions:
- The bone-kidney-parathyroid axis, mediated by FGF-23, is a crucial factor in pediatric CKD-MBD.
- Early detection and therapeutic targeting of FGF-23 may be vital for preventing skeletal complications in children with CKD.
- FGF-23 represents a promising novel therapeutic target even in the initial phases of pediatric CKD.
Abstract:
Disturbances in mineral and bone metabolism in children with chronic kidney disease (CKD) lead to specific abnormalities of skeletal homeostasis called CKD-mineral and bone disorder (CKD-MBD). These disturbances should be diagnosed and managed appropriately to prevent bone deformities and disturbed growth. Changes in the vitamin D and parathyroid hormone (PTH), and the subsequent alterations in calcium (Ca) and phosphate (P) homeostasis are considered responsible for the development of CKD-MBD. Recently, a phosphaturic hormone, the fibroblast growth factor-23 (FGF-23), has been reported as a key regulator of P and vitamin D metabolism. A number of recent studies in paediatric populations have documented that the FGF-23 levels are increased early in CKD, before any abnormalities in serum Ca, P or PTH are apparent. The elevated FGF-23 levels result in a negative P balance to maintain P homeostasis, inducing phosphaturia, independently of PTH, and suppressing vitamin D synthesis. Therefore, the bone-kidney-parathyroid endocrine axis mediated by FGF-23 should be a novel therapeutic target in clinical practice, even in early stages of CKD in children.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Chronic Kidney Disease I: Introduction
Skeleton and Calcium Homeostasis